Contact Information:

Virtual Exhibit Hall Home

Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on novel oncology therapeutics. Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on novel oncology therapeutics. ELZONRISÒ (tagraxofusp), a CD123-directed targeted therapy, is FDA-approved for treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a MAA is under review. ELZONRIS is in clinical trials for additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Pipeline candidates include: felezonexor (SL-801; XPO1 inhibitor; Phase 1 in advanced solid tumors), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in GBM completed), and SL-901 (novel kinase inhibitor; IND-enabling studies ongoing).

Elzonris Information

Prescribing Information